2018 Intermittent Claudication Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Intermittent Claudication Market

June 2018 | 70 pages | ID: 2B67A7CCFFCEN
VPAResearch

Abstracts

An estimated 40 million people suffer from Intermittent Claudication disease worldwide. The disease represents Plaque deposits in primary artery limit the volume of blood supplies to legs, which results in cramps when walking. Pain is primarily observed in calves and occasionally in thighs and buttocks. Intermittent Claudication is often considered as a key symptom of the peripheral arterial disease.

To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Intermittent Claudication pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Intermittent Claudication pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Intermittent Claudication pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.

Contents

1 TABLE OF CONTENTS

1.1 List of LIST OF FIGURES
1.2 List of Tables

2 INTERMITTENT CLAUDICATION PIPELINE ANALYSIS

2.1 Disease and Pipeline Overview
2.2 Intermittent Claudication Pipeline Snapshot
2.3 Intermittent Claudication Pipeline by Phase
2.4 Intermittent Claudication Pipeline by Company
2.5 Intermittent Claudication Pipeline by Mechanism of Action

3 INTERMITTENT CLAUDICATION- COMPANY WISE PIPELINE ANALYSIS

Aldagen, Inc
DNAVEC Corporation
Genovate Biotechnology
LTT Bio-Pharma Co.,Ltd.
Novartis International AG
Pluristem Therapeutics Inc

4 INTERMITTENT CLAUDICATION R&D PIPELINE SNAPSHOTS

Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/ License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details

5 RECENT DEVELOPMENTS IN INTERMITTENT CLAUDICATION PIPELINE

6 APPENDIX

6.1 About VPA Research
6.2 Sources and Research Methodology

List Of Figures

LIST OF FIGURES

Figure 1: Intermittent Claudication Pipeline by Phase, H2- 2018
Figure 2: Intermittent Claudication Pipeline by Companies, H2- 2018
Figure 3: Company Wise Pipeline Drug Phases, H2- 2018
Figure 4: Intermittent Claudication Pipeline by Mechanism of Action, H2- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H2- 2018

List Of Tables

LIST OF TABLES

Intermittent Claudication Pipeline by Phase, H2- 2018
Intermittent Claudication Pipeline by Companies, H2- 2018
Intermittent Claudication Pipeline by Mechanism of Action, H2- 2018
Table 1: Aldagen, Inc Intermittent Claudication Pipeline Drugs, H2- 2018
Table 2: DNAVEC Corporation Intermittent Claudication Pipeline Drugs, H2- 2018
Table 3: Genovate Biotechnology Intermittent Claudication Pipeline Drugs, H2- 2018
Table 4: LTT Bio-Pharma Co.,Ltd. Intermittent Claudication Pipeline Drugs, H2- 2018
Table 5: Novartis International AG Intermittent Claudication Pipeline Drugs, H2- 2018
Table 6: Pluristem Therapeutics Inc Intermittent Claudication Pipeline Drugs, H2- 2018